Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
25-26 September, 2025
Not Confirmed
Not Confirmed
29 September-02 October, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
25-26 September, 2025
Industry Trade Show
Not Confirmed
29 September-02 October, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/global-api-micronization-market-set-to-surge-49-by-2030-led-by-specialized-industry-pioneers
09 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/09/3146753/37216/en/Aclaris-Therapeutics-Announces-Late-Breaking-Abstract-and-Oral-Presentation-On-ATI-2138-Phase-2a-Results-at-the-2025-European-Academy-of-Dermatology-and-Venereology-EADV-Congress.html
27 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/27/3139973/37216/en/Aclaris-Therapeutics-to-Participate-in-Two-September-Healthcare-Conferences.html
07 Aug 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/08/07/3129042/37216/en/Aclaris-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Provides-Corporate-Update.html
29 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/29/3123590/37216/en/Aclaris-Therapeutics-Announces-Positive-Top-Line-Results-from-Open-Label-Phase-2a-Trial-of-ATI-2138-a-Potent-and-Selective-Investigational-Inhibitor-of-ITK-and-JAK3-Trial-Achieves-.html
28 Jul 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/07/28/3122487/37216/en/Aclaris-Therapeutics-Announces-Leadership-Transition.html
30 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/30/3107603/37216/en/Aclaris-Therapeutics-Added-to-the-Russell-2000-and-Russell-3000-Indexes.html
Details:
ATI-052 is a potential best-in-class bispecific antibody targets both thymic stromal lymphopoietin and interleukin-4 receptor. It is bein evaluated for the treatment of respiratory diseases.
Lead Product(s): ATI-052,Inapplicable
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: ATI-052
Study Phase: Phase IProduct Type: Antibody
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 23, 2025
Lead Product(s) : ATI-052,Inapplicable
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Starts Phase 1a/1b Trial for Novel Bispecific Antibody ATI-052 Program
Details : ATI-052 is a potential best-in-class bispecific antibody targets both thymic stromal lymphopoietin and interleukin-4 receptor. It is bein evaluated for the treatment of respiratory diseases.
Product Name : ATI-052
Product Type : Antibody
Upfront Cash : Inapplicable
June 23, 2025
Details:
ATI-045 (Bosakitug) is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.
Lead Product(s): Bosakitug,Inapplicable
Therapeutic Area: Dermatology Brand Name: ATI-045
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 10, 2025
Lead Product(s) : Bosakitug,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ATI-045 Versus Placebo in Patients with Moderate-to-Severe Atopic Dermatitis
Details : ATI-045 (Bosakitug) is a Antibody drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Dermatitis, Atopic.
Product Name : ATI-045
Product Type : Antibody
Upfront Cash : Inapplicable
June 10, 2025
Details:
ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases.
Lead Product(s): ATI-052,Inapplicable
Therapeutic Area: Immunology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 22, 2025
Lead Product(s) : ATI-052,Inapplicable
Therapeutic Area : Immunology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris gets FDA IND Clearance for ATI-052 Bispecific Antibody Trial
Details : ATI-052 is an investigational, potential best-in-class anti-TSLP/IL-4R bispecific monoclonal antibody being developed to treat certain immuno-inflammatory diseases.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
April 22, 2025
Details:
ATI-2138 is a novel investigational covalent inhibitor of ITK and JAK3 in development for the treatment of autoimmune and inflammatory diseases, like atopic dermatitis.
Lead Product(s): ATI-2138,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 12, 2025
Lead Product(s) : ATI-2138,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Study Highlights ATI-2138 As Selective ITK, JAK3 Inhibitor
Details : ATI-2138 is a novel investigational covalent inhibitor of ITK and JAK3 in development for the treatment of autoimmune and inflammatory diseases, like atopic dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 12, 2025
Details:
Aclaris gains worldwide rights (excluding Greater China) to BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R.
Lead Product(s): Bosakitug,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody
Recipient: Biosion
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 18, 2024
Lead Product(s) : Bosakitug,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Biosion
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Aclaris Announces Global License Agreement Adding Biologics Assets to Pipeline
Details : Aclaris gains worldwide rights (excluding Greater China) to BSI-045B, a novel anti-TSLP monoclonal antibody, and BSI-502, a novel bispecific antibody that is directed against both TSLP and IL4R.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 18, 2024
Details:
The company will use the proceeds to fund the research and development of its pipeline, including BSI-045B (bosakitug), a humanized monoclonal antibody targeting thymic stromal lymphopoietin.
Lead Product(s): Bosakitug,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody
Sponsor: Vivo Capital
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 18, 2024
Lead Product(s) : Bosakitug,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Vivo Capital
Deal Size : $80.0 million
Deal Type : Private Placement
Aclaris Therapeutics Announces $80 Million Private Placement
Details : The company will use the proceeds to fund the research and development of its pipeline, including BSI-045B (bosakitug), a humanized monoclonal antibody targeting thymic stromal lymphopoietin.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 18, 2024
Details:
ATI-1777 is an investigational topical soft JAK 1/3 inhibitor, small molecule drug. It is under phase 2 clinical development for the treatment of mild to severe atopic dermatitis.
Lead Product(s): ATI-1777,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 01, 2024
Lead Product(s) : ATI-1777,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Announces Top-Line Results from Phase 2b Trial of ATI-1777 for Dermatitis
Details : ATI-1777 is an investigational topical soft JAK 1/3 inhibitor, small molecule drug. It is under phase 2 clinical development for the treatment of mild to severe atopic dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2024
Details:
ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3. Currently, it is being evaluated for the treatment of Moderate to Severe Atopic Dermatitis.
Lead Product(s): ATI-2138,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 17, 2024
Lead Product(s) : ATI-2138,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Aclaris Doses First Patient in Phase 2a Trial of ATI-2138 for Atopic Dermatitis
Details : ATI-2138 is an investigational oral covalent inhibitor of ITK, and JAK3. Currently, it is being evaluated for the treatment of Moderate to Severe Atopic Dermatitis.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 17, 2024
Details:
Undisclosed
Lead Product(s): ATI-2138,Inapplicable
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 05, 2024
Lead Product(s) : ATI-2138,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 05, 2024
Details:
OLUMIANT (baricitinib) is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Lead Product(s): Baricitinib,Inapplicable
Therapeutic Area: Dermatology Brand Name: Olumiant
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Eli Lilly
Deal Size: $31.5 million Upfront Cash: $26.5 million
Deal Type: Licensing Agreement July 16, 2024
Lead Product(s) : Baricitinib,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Eli Lilly
Deal Size : $31.5 million
Deal Type : Licensing Agreement
Aclaris Sells OLUMIANT® Royalties to OMERS for Up to $315M
Details : OLUMIANT (baricitinib) is the first and only JAK inhibitor FDA-approved for the treatment of COVID-19 in certain hospitalized adults requiring various degrees of oxygen support.
Product Name : Olumiant
Product Type : Other Small Molecule
Upfront Cash : $26.5 million
July 16, 2024
ABOUT THIS PAGE